Jun 25, 2019   SOURCE: PR NewsWire

Global Myelofibrosis Market 2017-2018 & 2019-2026: Celgene's $1.1bn Impact Buy is First of More Deals to Come in 2018 and Beyond

DUBLIN, June 25, 2019 /PRNewswire/ -- The "Market Spotlight: Myelofibrosis" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Myelofibrosis market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts

Key Takeaways

    --  The author estimates that in 2017, there were 47,000 prevalent cases of
        myelofibrosis in adults aged 50 years and older worldwide, and forecasts
        that number to increase to 58,300 prevalent cases by 2026.
    --  The global prevalence of myelofibrosis is estimated to be 0.0027%.
        Incyte's Jakafi (ruxolitinib phosphate) is the only marketed drug for
        myelofibrosis. It is the first FDA-approved oral JAK1/2 inhibitor for
        the treatment of the disease.
    --  The majority of industry-sponsored drugs in active clinical development
        for myelofibrosis are in Phase II, with only two drugs in Phase III.
    --  Therapies in mid-to-late-stage development for myelofibrosis focus on a
        wide variety of targets. The majority of the pipeline drugs are
        administered via the oral route.
    --  High-impact upcoming events for drugs in the myelofibrosis space
        comprise topline Phase II trial results and an expected CHMP opinion for
        pacritinib.
    --  The overall likelihood of approval of a Phase I hematologic asset is
        10.7%, and the average probability a drug advances from Phase III is
        57.6%. Drugs, on average, take 8.7 years from Phase I to approval,
        compared to 9.2 years in the overall oncology space.
    --  There were only three licensing and asset acquisition deals involving
        myelofibrosis drugs during 2014-18. The largest deal was the $1,250m
        agreement in 2015 between Bristol-Myers Squibb and Promedior, pursuant
        to which Bristol-Myers Squibb was granted an exclusive right to acquire
        Promedior along with its lead asset PRM-151, which is in development for
        idiopathic pulmonary fibrosis and myelofibrosis.
    --  The distribution of clinical trials across Phase I-IV indicates that the
        majority of trials for myelofibrosis have been in the early and
        mid-phases of development, with 88% of trials in Phase I-II, and only
        12% in Phase III-IV.
    --  The US has a substantial lead in the number of myelofibrosis clinical
        trials globally. Germany leads the major EU markets, while Israel has
        the top spot in Asia.
    --  Clinical trial activity in the myelofibrosis space is dominated by
        completed trials. Novartis has the highest number of completed clinical
        trials for myelofibrosis, with 12 trials.
    --  Novartis leads industry sponsors with the highest number of clinical
        trials for myelofibrosis, followed by Incyte.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Anemia
Splenomegaly
Curative treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
Four Drugs Set For EU Approval, EMA Holds Fire On Pacritinib
Moment Of Truth For Pacritinib And Other EU Approval Hopefuls

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS
Geron Has Cash, But Does It Have The Imetelstat Data To Push On Without Janssen?
Sierra Believes It Can Do Better Than Gilead With JAK Inhibitor Momelotinib
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
Recent events

BIBLIOGRAPHY
Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/dx1lg6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-myelofibrosis-market-2017-2018--2019-2026-celgenes-1-1bn-impact-buy-is-first-of-more-deals-to-come-in-2018-and-beyond-300873399.html

SOURCE Research and Markets